These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 28432802)

  • 1. Subsequent malignancies after allogeneic hematopoietic stem cell transplantation.
    Gündüz M; Özen M; Şahin U; Toprak SK; Civriz Bozdağ S; Kurt Yüksel M; Arslan Ö; Özcan M; Demirer T; Beksaç M; İlhan O; Gürman G; Topçuoğlu P
    Clin Transplant; 2017 Jul; 31(7):. PubMed ID: 28432802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T-cell-replete hematopoietic stem cell transplantation: incidence and risk factors.
    Yan CH; Liu DH; Xu LP; Liu KY; Zhao T; Wang Y; Chen H; Chen YH; Han W; Huang XJ
    Clin Transplant; 2012; 26(6):868-76. PubMed ID: 22432715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors.
    Remberger M; Ringdén O; Hägglund H; Svahn BM; Ljungman P; Uhlin M; Mattsson J
    Clin Transplant; 2013; 27(4):E368-74. PubMed ID: 23701240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuing increased risk of oral/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft-versus-host disease.
    Atsuta Y; Suzuki R; Yamashita T; Fukuda T; Miyamura K; Taniguchi S; Iida H; Uchida T; Ikegame K; Takahashi S; Kato K; Kawa K; Nagamura-Inoue T; Morishima Y; Sakamaki H; Kodera Y;
    Ann Oncol; 2014 Feb; 25(2):435-41. PubMed ID: 24399081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epileptic seizures in patients following allogeneic hematopoietic stem cell transplantation: a retrospective analysis of incidence, risk factors, and survival rates.
    Zhang XH; Xu LP; Liu DH; Chen H; Han W; Chen YH; Wang FR; Wang JZ; Wang Y; Zhao T; Chen Y; Fu HX; Liu KY; Huang XJ
    Clin Transplant; 2013; 27(1):80-9. PubMed ID: 22938074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral blood late mixed chimerism in leucocyte subpopulations following allogeneic stem cell transplantation for childhood malignancies: does it matter?
    Pichler H; Fritsch G; König M; Daxberger H; Glogova E; Pötschger U; Breuer S; Lawitschka A; Güclü ED; Karlhuber S; Holter W; Haas OA; Lion T; Matthes-Martin S
    Br J Haematol; 2016 Jun; 173(6):905-17. PubMed ID: 26996395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical analysis of 104 patients with hematological malignancy after allogeneic hemotopoietic stem cell transplantation].
    Chen Y; Xu Y; Zhu Y; Fu G; Liu Y; Peng J; Fu B; He Q; Wu D; Li X; Zhao X; Chen F
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Sep; 36(9):859-64. PubMed ID: 21946205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of low-dose mycophenolate mofetil with cyclosporine and methotrexate as GVHD prophylaxis in unrelated donor allogeneic stem cell transplantation.
    Zhu X; Lai X; Luo Y; Shi J; Tan Y; Zheng W; He J; Xie W; Li L; Zhang J; Ye X; Lin M; Cai Z; Huang H
    Leuk Res; 2013 Sep; 37(9):1046-51. PubMed ID: 23849987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens.
    Abou-Mourad YR; Lau BC; Barnett MJ; Forrest DL; Hogge DE; Nantel SH; Nevill TJ; Shepherd JD; Smith CA; Song KW; Sutherland HJ; Toze CL; Lavoie JC
    Bone Marrow Transplant; 2010 Feb; 45(2):295-302. PubMed ID: 19597425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical analysis of acute renal failure after allogeneic hematopoietic stem cell transplantation].
    Zhou T; Cen XN; Qiu ZX; Ou JP; Wang WS; Xu WL; Li Y; Wang MJ; Wang LH; Tong YJ; Ren HY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):723-8. PubMed ID: 19549395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients.
    Liao YP; Jiang JL; Zou WY; Xu DR; Li J
    World J Gastroenterol; 2015 Apr; 21(14):4284-92. PubMed ID: 25892880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The risk factors of post-transplant lymphoproliferative disorders following haploidentical hematopoietic stem cell transplantation].
    Zhang C; Huang X; Liu D; Mo X; Zhang X; Chen H; Han W; Chen Y; Wang Y; Wang J; Wang F; Zhao T; Liu Y; Liu K; Xu L
    Zhonghua Nei Ke Za Zhi; 2014 Jul; 53(7):527-31. PubMed ID: 25264006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed death 1 ligand (PD-L1) in solid cancers after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Nagasaki Transplant Group.
    Kasai S; Itonaga H; Niino D; Miyoshi H; Kato T; Imanishi D; Fujioka M; Furumoto T; Sato S; Sawayama Y; Taguchi J; Imaizumi Y; Hata T; Yoshida S; Moriuchi Y; Ohshima K; Miyazaki Y
    Int J Hematol; 2020 Oct; 112(4):524-534. PubMed ID: 32588395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.
    Zallio F; Primon V; Tamiazzo S; Pini M; Baraldi A; Corsetti MT; Gotta F; Bertassello C; Salvi F; Rocchetti A; Levis A
    Clin Transplant; 2013; 27(4):E491-7. PubMed ID: 23781897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility of tacrolimus, methotrexate, and prednisolone as a graft-versus-host disease prophylaxis in non-T-cell-depleted haploidentical hematopoietic stem cell transplantation for children.
    Mochizuki K; Kikuta A; Ito M; Sano H; Akaihata M; Kobayashi S; Ohto H; Hosoya M
    Clin Transplant; 2011; 25(6):892-7. PubMed ID: 21070366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cell composition of infused donor lymphocyte has different impact in different types of allogeneic hematopoietic stem cell transplantation.
    Zhao XS; Wang Y; Yan CH; Wang JZ; Zhang XH; Xu LP; Liu KY; Huang XJ
    Clin Transplant; 2014 Aug; 28(8):926-34. PubMed ID: 24931494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver graft-versus-host disease after donor lymphocyte infusion for relapses of hematologic malignancies post allogeneic hematopoietic stem cell transplantation.
    Ma SY; Au WY; Lie AK; Ng IO; Leung AY; Tse EW; Liang RH; Lau GK; Kwong YL
    Bone Marrow Transplant; 2004 Jul; 34(1):57-61. PubMed ID: 15156162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analysis of risk factors for relapse of 82 patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation].
    Yu ZP; Ding JH; Chen BA; Wu F; Gao C; Sun YY; Chen J; Zhao G; Wang J; Li YF; Ding BH; Qian J
    Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):283-6. PubMed ID: 21575500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease.
    de Lima M; Bonamino M; Vasconcelos Z; Colares M; Diamond H; Zalcberg I; Tavares R; Lerner D; Byington R; Bouzas L; da Matta J; Andrade C; Carvalho L; Pires V; Barone B; Maciel C; Tabak D
    Bone Marrow Transplant; 2001 Jan; 27(1):73-8. PubMed ID: 11244440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.